Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity.
Jan KrhutPeter WohlfahrtJiří PudichEliška KufováVladimír BorovičkaKarolína BílkováRadek SýkoraJan MokrišRenata CífkováRoman ZachovalPeter ZvaraPublished in: International urology and nephrology (2021)
Our results suggest that mirabegron can be safely used in the treatment of patients with SCI- and MS-induced NDO.